Literature DB >> 8009849

Microevolution of Sabin 1 strain in vitro and genetic stability of oral poliovirus vaccine.

G V Rezapkin1, K M Chumakov, Z Lu, Y Ran, E M Dragunsky, I S Levenbook.   

Abstract

Mutants consistently accumulating in Sabin 1 poliovirus during serial passaging in vitro were identified by sequence heterogeneity assay and quantitated using mutant analysis by PCR and restriction enzyme cleavage (MAPREC). Only four unstable genomic sites were identified in virus passaged 10 times in African green monkey kidney (AGMK) cells, and eight sites in virus passaged in Vero cells. Mutations accumulated both in untranslated regions of RNA (nucleotides 480, 525 and 7441) and in coding sequences, as missense (nucleotides 1449, 4944, and 6203) or silent (nucleotides 1123 and 1141) mutations. The most prominent selectable mutations were found at complementary nucleotides 480 and 525 of the 5'-untranslated region (5'-UTR) of the Sabin strain, changing the G:U pair in F-domain to either A:U or G:C variants. These two variants have been shown previously to have an increased neurovirulence in monkeys. The G:C variant accumulated during passage in Vero cells, while A:U variant accumulated in CV-1 cells. Virus passaged in AGMK cells accumulated both variants. Higher temperature (37 instead of 34 degrees) strongly favored selection of mutants in Vero cells, had a smaller effect on mutant accumulation in AGMK cells, and had no effect in CV-1 cells. Monopools of type 1 oral poliovirus vaccine (OPV) made by seven manufacturers were found to contain both 480-A and 525-C revertants at a combined level of 1.1-2.7%. Viral samples with increased amounts of these revertants had higher neurovirulence in monkeys. Our results suggest that quantitation of these reversions by MAPREC may be prognostic for results of the monkey neurovirulence test (MNVT) and can be used for monitoring type 1 OPV consistency.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8009849     DOI: 10.1006/viro.1994.1353

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  17 in total

1.  Neurovirulence of type 1 polioviruses isolated from sewage in Japan.

Authors:  Hitoshi Horie; Hiromu Yoshida; Kumiko Matsuura; Miwako Miyazawa; Yoshihiro Ota; Takashi Nakayama; Yutaka Doi; So Hashizume
Journal:  Appl Environ Microbiol       Date:  2002-01       Impact factor: 4.792

2.  Correlation of mutations and recombination with growth kinetics of poliovirus vaccine strains.

Authors:  V Pliaka; Z Kyriakopoulou; D Tsakogiannis; I G A Ruether; C Gartzonika; S Levidiotou-Stefanou; A Krikelis; P Markoulatos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-05       Impact factor: 3.267

3.  Massively parallel sequencing for monitoring genetic consistency and quality control of live viral vaccines.

Authors:  Alexander Neverov; Konstantin Chumakov
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

4.  Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis.

Authors:  M M Georgescu; J Balanant; A Macadam; D Otelea; M Combiescu; A A Combiescu; R Crainic; F Delpeyroux
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

5.  PCR engineering of viral quasispecies: a new method to preserve and manipulate genetic diversity of RNA virus populations.

Authors:  K M Chumakov
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

Review 6.  Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis.

Authors:  P Muir; U Kämmerer; K Korn; M N Mulders; T Pöyry; B Weissbrich; R Kandolf; G M Cleator; A M van Loon
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

Review 7.  Current status of poliovirus infections.

Authors:  J L Melnick
Journal:  Clin Microbiol Rev       Date:  1996-07       Impact factor: 26.132

8.  Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Jong-Hoon Kim; Cara C Burns; Olen M Kew; M Steven Oberste; Ousmane M Diop; Steven G F Wassilak; Stephen L Cochi; Kimberly M Thompson
Journal:  Risk Anal       Date:  2013-03-07       Impact factor: 4.000

9.  Mutation of a single conserved nucleotide between the cloverleaf and internal ribosome entry site attenuates poliovirus neurovirulence.

Authors:  Nidia De Jesus; David Franco; Aniko Paul; Eckard Wimmer; Jeronimo Cello
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

10.  Growth kinetic analysis of bi-recombinant poliovirus vaccine strains.

Authors:  Vaia Pliaka; Evaggelos Dedepsidis; Zaharoula Kyriakopoulou; Georgia Papadi; Dimitris Tsakogiannis; Anastassia Pratti; Stamatina Levidiotou-Stefanou; Panayotis Markoulatos
Journal:  Virus Genes       Date:  2010-01-21       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.